Journal of Cardiovascular Translational Research

, Volume 7, Issue 1, pp 91–100

Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

  • Stefanie Schulz
  • Dominick J. Angiolillo
  • David Antoniucci
  • Isabell Bernlochner
  • Christian Hamm
  • Juliane Jaitner
  • Karl-Ludwig Laugwitz
  • Katharina Mayer
  • Barbara von Merzljak
  • Tanja Morath
  • Franz-Josef Neumann
  • Gert Richardt
  • Judith Ruf
  • Gisela Schömig
  • Helmut Schühlen
  • Heribert Schunkert
  • Adnan Kastrati
  • Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators
Article

DOI: 10.1007/s12265-013-9527-3

Cite this article as:
Schulz, S., Angiolillo, D.J., Antoniucci, D. et al. J. of Cardiovasc. Trans. Res. (2014) 7: 91. doi:10.1007/s12265-013-9527-3

Abstract

In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.

Keywords

TicagrelorPrasugrelAcute coronary syndromePCI

Abbreviations

ACS

Acute coronary syndrome

ADP

Adenosine diphosphate

ASA

Acetylsalicylic acid

CABG

Coronary artery bypass graft

ISAR-REACT

Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment

LBBB

Left bundle branch block

MRI

Magnetic resonance imaging

NSTE–ACS

Non-ST segment elevation acute coronary syndrome

NSTEMI

Non-ST segment elevation myocardial infarction

PCI

Percutaneous coronary intervention

STEMI

ST segment elevation myocardial infarction

URL

Upper reference limit

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Stefanie Schulz
    • 1
    • 11
  • Dominick J. Angiolillo
    • 2
  • David Antoniucci
    • 3
  • Isabell Bernlochner
    • 4
  • Christian Hamm
    • 5
    • 10
  • Juliane Jaitner
    • 4
  • Karl-Ludwig Laugwitz
    • 4
    • 9
  • Katharina Mayer
    • 1
  • Barbara von Merzljak
    • 1
  • Tanja Morath
    • 1
  • Franz-Josef Neumann
    • 6
  • Gert Richardt
    • 7
  • Judith Ruf
    • 1
  • Gisela Schömig
    • 1
  • Helmut Schühlen
    • 8
  • Heribert Schunkert
    • 1
    • 9
  • Adnan Kastrati
    • 1
    • 9
  • Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators
  1. 1.Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
  2. 2.University of Florida College of MedicineJacksonvilleUSA
  3. 3.Careggi Hospital FirenzeFlorenceItaly
  4. 4.1. Medizinische Klinik, Klinikum rechts der IsarTechnische Universität MünchenMunichGermany
  5. 5.Kerckhoff KlinikBad NauheimGermany
  6. 6.Herzzentrum Bad KrozingenBad KrozingenGermany
  7. 7.Herzzentrum der Segeberger KlinikenBad SegebergGermany
  8. 8.Vivantes, Auguste-Viktoria-KlinikumBerlinGermany
  9. 9.DZHK, Partner Site Munich Heart AllianceMunichGermany
  10. 10.DZHK, Partner Site Rhine-MainFrankfurtGermany
  11. 11.ISAResearch CenterDeutsches Herzzentrum MünchenMunichGermany